Mostrar el registro sencillo del ítem
dc.contributor.author
Brenta, Gabriela
dc.contributor.author
Berg, Gabriela Alicia
dc.contributor.author
Miksztowicz, Verónica Julieta
dc.contributor.author
Lopez, Graciela Ines
dc.contributor.author
Lucero, Diego Martín
dc.contributor.author
Faingold, María Cristina
dc.contributor.author
Murakami, Masami
dc.contributor.author
Machima, Tetsudo
dc.contributor.author
Nakajima, Katsuyuki
dc.contributor.author
Schreier, Laura Ester
dc.date.available
2018-03-19T21:35:07Z
dc.date.issued
2016-03
dc.identifier.citation
Brenta, Gabriela; Berg, Gabriela Alicia; Miksztowicz, Verónica Julieta; Lopez, Graciela Ines; Lucero, Diego Martín; et al.; Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine; Mary Ann Liebert; Thyroid; 26; 3; 3-2016; 365-372
dc.identifier.issn
1050-7256
dc.identifier.uri
http://hdl.handle.net/11336/39313
dc.description.abstract
Background: Qualitative lipoprotein changes, such as an increase in fasting remnants, are reported in subclinical hypothyroidism (SCH). It was hypothesized that such changes are due to reduced hepatic lipase (HL) activity in SCH: HL is an enzyme regulated by thyroid hormones, and is involved in the degradation of triglyceride (TG)-rich remnants. This study aimed to quantify remnant-like lipoproteins (RLP), small dense LDL (sdLDL), and HL activity in women with SCH, and to assess these parameters after levothyroxine replacement therapy. Methods: This was an observational cross-sectional study with a subsequent longitudinal follow-up. Findings in women with thyrotropin levels >4.5 mIU/L (SH group) were compared with age- and body mass index (BMI)-matched euthyroid women (control group). In addition, a subgroup analysis was undertaken in SCH women who chose to receive levothyroxine treatment (0.9 μg/kg/day) for 6 months. RLP was quantified by measuring cholesterol (RLP-C) and triglycerides (RLP-TG) after immunoaffinity chromatography, and sdLDL by automated standardized methods; HL activity was measured in post-heparin plasma. Results: The SCH group included 37 women; 29 women were included in the control group. In addition, 22 women with SCH were included in the subgroup analysis (levothyroxine treatment). Significantly higher RLP values were observed in the SCH group than in the control group: RLP-C (median [range], mg/dL): 20.3 (5.8-66.8) versus 10.2 (2.7-36.3), p = 0.005; RLP-TG (mg/dL): 26.3 (3.2-123.3) versus 12.1 (2.5-61.6), p = 0.033. HL activity (mean ± standard deviation [SD], μmol free fatty acid/mL post-heparin plasma.h) - 9.83 ± 4.25 versus 9.92 ± 5.20, p = 0.707 - and sdLDL levels (mg/dL) - 23.1 ± 10.7 versus 22.6 ± 8.4, p = 0.83 - were similar. After levothyroxine, RLP-C decreased - 21.5 (5.8-66.8) versus 17.2 (4.1-45.6), p = 0.023 - and HL increased - 9.75 ± 4.04 versus 11.86 ± 4.58, p = 0.012 - in the subgroup of SCH women. No changes in sdLDL were observed. Conclusions: Women with SCH have higher RLP levels than matched controls do, but their RLP-C levels decrease significantly following levothyroxine therapy. Furthermore, HL activity also increases after levothyroxine therapy and can be interpreted as a possible explanation for the decrease in RLP-C.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Mary Ann Liebert
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Lipoproteins
dc.subject
Subclinical Hypothyroidism
dc.subject
Hepatic Lipase Activity
dc.subject
Cardiovascular Risk
dc.subject.classification
Otras Ciencias de la Salud
dc.subject.classification
Ciencias de la Salud
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2018-03-15T14:05:46Z
dc.journal.volume
26
dc.journal.number
3
dc.journal.pagination
365-372
dc.journal.pais
Estados Unidos
dc.description.fil
Fil: Brenta, Gabriela. Unidad Asistencial Doctor César Milstein; Argentina
dc.description.fil
Fil: Berg, Gabriela Alicia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Miksztowicz, Verónica Julieta. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Lopez, Graciela Ines. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Lucero, Diego Martín. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Faingold, María Cristina. Unidad Asistencial Doctor César Milstein; Argentina
dc.description.fil
Fil: Murakami, Masami. Gunma University Graduate School Of Medicine; Japón
dc.description.fil
Fil: Machima, Tetsudo. Gunma University Graduate School Of Medicine; Japón
dc.description.fil
Fil: Nakajima, Katsuyuki. Graduate School Of Health Sciences, Gunma University; Japón
dc.description.fil
Fil: Schreier, Laura Ester. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.journal.title
Thyroid
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1089/thy.2015.0140
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.liebertpub.com/doi/10.1089/thy.2015.0140
Archivos asociados